07:00 , Sep 18, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Chris Cain, Associate Editor, and Kai-Jye Lou, Senior Writer RNA sequencing standardized The FDA has convened a consortium to review the status of RNA sequencing for drug development and outline hurdles for incorporating the technology...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Burnet Institute, Artes Biotechnology, Program for Appropriate Technology in Health deal

Burnet Institute and Artes partnered to develop vaccines to prevent transmission of malaria infection from mosquitos to humans. The project has undisclosed funding from the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Artes Biotechnology, PT Bio Farma deal

Artes and vaccine manufacturer PT Bio Farma partnered to develop and manufacture virus-like particle (VLP)-based vaccines. Artes will contribute its Metavax duck HBV VLP technology. PT Bio Farma did not respond in time for publication,...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Artes Biotechnology GmbH, J&J deal

Artes and Crucell, which is part of Johnson & Johnson, partnered to develop two vaccines based on Artes' yeast-based virus like particle (VLP) technology and Hansenula polymorpha expression system. Artes is responsible for the delivery...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

Artes Biotechnology GmbH, Select Vaccines deal

Artes acquired Anavax virus-like particle (VLP) technology from Select Vaccines for an undisclosed upfront payment. Anavax also is eligible for double-digit royalties. Select Vaccines plans to combine the technology with its Hansenula polymorpha yeast production...
07:00 , May 10, 2010 |  BC Week In Review  |  Company News

Artes Biotechnology, Q Chip deal

The companies partnered to develop monthly sustained-release formulations of interferon alpha 2a to treat HCV and HBV. The partners will evaluate Q Chip's Q-Sphera peptide and protein delivery technology with interferon alpha 2a produced using...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Company News

Anika, Artes sales and marketing update

Anika ended a July deal under which Artes became the exclusive distributor of Anika's Elevess to U.S. dermatologists, plastic surgeons and cosmetic surgeons. Anika will service customers itself while it seeks a new U.S. distribution...
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Artes dermatology news

Artes hired JMP Securities LLC to explore strategic alternatives while the company continues to seek equity and debt transactions to raise money. Artes markets ArteFill , polymethylmethacrylate (PMMA) microspheres suspended in ultra-purified U.S. bovine collagen...
07:00 , Oct 27, 2008 |  BC Week In Review  |  Clinical News

ArteFill: Post-marketing study completed enrollment

Artes completed enrollment of 1,000 patients in a 5-year, U.S. post-marketing study of ArteFill. The product was approved for the indication by FDA in October 2006. Artes Medical Inc. (NASDAQ:ARTE), San Diego, Calif.   Product:...
07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

Artes management update

Artes Medical Inc. (NASDAQ:ARTE), San Diego, Calif.   Business: Dermatology   Promoted: Michael Green to COO while remaining CFO  ...